Suvorexant 10 mg

DRUG4 trials

Sponsors

Henry Ford Health System, Mclean Hospital, Walter Reed Army Institute of Research (WRAIR), Ohio State University

Conditions

Alcohol Use DisorderInsomniaNicotine DependencePerformance Enhancing Product Use

Early Phase 1

A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study

Active, not recruitingNCT04273776

Walter Reed Army Institute of Research (WRAIR)Performance Enhancing Product Use

Start: 2019-12-01End: 2025-12-12Target: 90Updated: 2025-04-03

Phase 1

Targeting Orexin to Treat Nicotine Dependence

Active, not recruitingNCT03999099

Mclean HospitalNicotine Dependence

Start: 2019-09-26End: 2026-12-31Target: 45Updated: 2026-07-14

Phase 2

Orexin Receptor Antagonism for the Treatment of Alcohol Use Disorder and Stress-Related Drinking

RecruitingNCT07214207

Ohio State UniversityAlcohol Use Disorder

Start: 2025-12-04End: 2030-09-30Target: 250Updated: 2025-12-11

Phase 4

Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs

CompletedNCT03312517

Henry Ford Health SystemInsomnia

Start: 2018-04-15End: 2018-10-25Updated: 2019-11-01

Related Papers

Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep?

2019-09-016 citations